Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)
This study has been completed.
Sponsor:
Ontario Clinical Oncology Group (OCOG)
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier:
NCT00391248
First received: October 19, 2006
Last updated: January 28, 2013
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To improve the clinical outcomes of patients with non-small cell lung cancer treated with radiation therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Non-small Cell Lung Cancer |
Drug: Erlotinib |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial) |
Resource links provided by NLM:
Further study details as provided by Ontario Clinical Oncology Group (OCOG):
Primary Outcome Measures:
- The mean improvement of "lung cancer symptoms" as measured by the Lung Cancer Symptom Scale at four weeks following completion of radiation therapy [ Time Frame: 4 weeks post radiotherapy ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The improvement in global quality of life and total scores of the LCSS at four weeks following treatment, radiological response, and the incidence and severity of adverse events as per the CTCAE version 3 [ Time Frame: 4 weeks post radiotherapy ] [ Designated as safety issue: No ]
| Enrollment: | 40 |
| Study Start Date: | November 2006 |
| Study Completion Date: | December 2012 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Erlotinib
150 mg in a single daily dose, starting Day 1 through Day 22
Other Name: Tarceva
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically confirmed non-small cell lung cancer (squamous cell, adenocarcinoma, poorly differentiated non-small cell carcinoma, or some combination of these); and
- Symptomatic patients (defined at discretion of investigator) for whom palliative thoracic radiation is planned (3000cGy/10 fractions); and
- At least 18 years of age.
Exclusion Criteria:
- Previous erlotinib therapy; or
- Planned concurrent chemotherapy; or
- Expected survival of less than 3 months; or
- ECOG Performance Status of 3 or 4; or
- Multiple CNS metastasis or a single CNS lesion that has not demonstrated radiologic stability (screening CT/MRI or head not required); or
- Granulocyte count <1,500/mm3, platelet count <100,000/mm3, or haemoglobin <9.0g/dl; or
- SGOT (AST) or SGPT (ALT) > 2.5 times (x) upper limit of normal (ULN) in the absence of known liver metastases or > 5 x ULN in case of known liver metastases; or
- Alkaline phosphatase (ALP) > 2.5 x ULN; or
- Serum bilirubin > 1.5 ULN; or
- Serum creatinine > 1.5 ULN or creatinine clearance < 60 ml/min; or
- Serum calcium beyond ULN; or
- Patients requiring systemic anti-fungal therapy, clarithromycin, phenytoin, or oral anticoagulation therapy (see Appendix VI for complete list of medications); or
- A history of interstitial lung disease; or
- Known sensitivity to erlotinib; or
- Pregnancy, lactation, or parturition within the previous 30 days; or
- Unwillingness or inability to complete the required assessments of the trial; or
- Mental incompetence, including psychiatric or addictive disorders which would preclude meaningful informed consent; or
- History of recurrent conjunctivitis or keratitis or other inflammatory changes of the surface of the eye.
- Geographically inaccessible for treatment or follow-up evaluations; or
- Involved in an ongoing therapeutic trial.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00391248
Locations
| Canada, Ontario | |
| Juravinski Cancer Centre | |
| Hamilton, Ontario, Canada, L8V 1C3 | |
| Toronto Sunnybrook Regional Cancer Centre | |
| Toronto, Ontario, Canada, M5N 3M5 | |
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Roche Pharma AG
Investigators
| Principal Investigator: | Jim Wright, MD | Juravinski Cancer Centre |
More Information
No publications provided
| Responsible Party: | Ontario Clinical Oncology Group (OCOG) |
| ClinicalTrials.gov Identifier: | NCT00391248 History of Changes |
| Other Study ID Numbers: | CTA-Control-105472 |
| Study First Received: | October 19, 2006 |
| Last Updated: | January 28, 2013 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Ontario Clinical Oncology Group (OCOG):
|
non-small cell lung cancer palliative radiation tarceva palliative thoracic radiation therapy |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Erlotinib Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013